Serum interferon β-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients

Neurology

Volumn 51, Issue 3, 1998, Pages 738-742

  Khan, Omar A ^a   Dhib Jalbut, Suhayl S ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CROSS REACTION; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LABELING INDEX; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0031720695     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.738     Document Type: Article

References (14)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Jacobs LD, Cockfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
3. Mark DV, Lu SD, Creasey A, et al. Site-specific mutagenesis of the human fibroblast interferon gene. Proc Natl Acad Sci USA 1984;81:5662-5666.
4. Pharmacokinetic analysis for TB01-1102. Phase 1 study to evaluate the pharmacokinetics and safety of human recombinant beta interferon (Betaseron) given intravenously and subcutaneously in healthy normal volunteers. Report on file, Berlex Laboratories, Inc., Richmond, CA.
5. Alam J, McAllister A, Scaramucci J, Jones W, Rogge M. Pharmacokinetics and pharmacodynamics of interferon beta-1a in healthy volunteer after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 1997;14:35-43.
6. Alam J, Goelz S, Rioux P, et al. Comparative pharmacokinetics of two recombinant human interferon beta-1a products administered intramuscularly in healthy male and female volunteers. Pharmaceutical Res 1997;14:546-549.
7. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996). Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
8. Khan OA, Xia Q, Bever CT, Johnson KP, Panitch HS, DhibJalbut SS. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996;46:1639-1643.
9. Yamazaki S, Kuramoto K, Matsuo E, Hosoi K, Hara M, Shimizu H. Highly sensitive enzyme immunoassay of human interferon-β1. J Immunoassay 1989;10:57-73.
10. Pachner AR. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology 1997;49:647-650.
11. Hawkins MJ, Krown SE, Borden EC, et al. American cancer society phase I trial of naturally produced β-interferon. Cancer Res 1984;44:5934-5938.
12. Goldstein D, Sielaff KM, Storer BE, et al. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J Natl Cancer Inst 1989;81:1061-1068.
13. Borden EC, Edwards BS, Hawkins MJ, Merritt JA. Interferons: biological response modification and pharmacology. In: Milich E, ed. Biological responses in cancer. New York: Plenum, 1982:169-218.
14. Ebers GC, Oger J, Paty D, et al. The Multiple Sclerosis PRISMS Study: prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis. Ann Neurol 1997;42:986. Abstract.